Condition
Diabetes Mellitus, Type 2
Obesity
Overweight
Locations
Germany
Start date
20/08/2024
Identifiers
Trial ID
NN9490-7611,
NCT number NCT06559527,
Eudract number Not Available
NCT number NCT06559527,
Eudract number Not Available
Summary
Novo Nordisk is developing the study medicine NNC0487-0111 to treat people living with type 2 diabetes and/or people living with overweight or obesity. The aim of this study is to see if blood levels of NNC0487-0111 are the same in people living with various degrees of reduced kidney function as for people with normal kidney function. Participants will be given one single injection by the study staff in a skinfold in their stomach using a pen device (NovoPen®4).
Trial Overview:
Treatment
DRUG: NNC0487-0111
Study type
INTERVENTIONAL
Trial duration
Aug 20 2024 - Feb 25 2025
Participants
42
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 80 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.